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Aim To compare the performance of iohexol plasma clear-
ance and creatinine-based renal function estimating equa-
tions in monitoring longitudinal renal function changes in 
chronic heart failure (CHF) patients, and to assess the ef-
fects of body composition on the equation performance.
Methods Iohexol plasma clearance was measured in 43 
CHF patients at baseline and after at least 6 months. Simul-
taneously, renal function was estimated with five creati-
nine-based equations (four- and six-variable Modification 
of Diet in Renal Disease, Cockcroft-Gault, Cockcroft-Gault 
adjusted for lean body mass, Chronic Kidney Disease Epi-
demiology Collaboration equation) and body composition 
was assessed using bioimpedance and dual-energy x-ray 
absorptiometry.
Results Over a median follow-up of 7.5 months (range 
6-17 months), iohexol clearance significantly declined 
(52.8 vs 44.4 mL/[min ×1.73 m2], P = 0.001). This decline 
was significantly higher in patients receiving mineralo-
corticoid receptor antagonists at baseline (mean decline 
-22% of baseline value vs -3%, P = 0.037). Mean serum cre-
atinine concentration did not change significantly during 
follow-up and no creatinine-based renal function estimat-
ing equation was able to detect the significant longitudi-
nal decline of renal function determined by iohexol clear-
ance. After accounting for body composition, the accuracy 
of the equations improved, but not their ability to detect 
renal function decline.
Conclusions Renal function measured with iohexol plas-
ma clearance showed relevant decline in CHF patients, 
particularly in those treated with mineralocorticoid recep-
tor antagonists. None of the equations for renal function 
estimation was able to detect these changes.
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Renal function is one of the key clinical parameters to 
be monitored in heart failure patients; it predicts mortal-
ity and can be crucial for making therapeutic decisions 
(1,2). The “gold standard” for renal function assessment is 
the measurement of inulin clearance, which is difficult to 
perform and not feasible in routine work (3). An alterna-
tive approach is measurement of iohexol clearance, which 
correlates well with inulin clearance and is considered a ro-
bust standard for evaluating renal function (4,5). In clini-
cal practice, renal function is also estimated by equations 
based on serum creatinine concentration, for example, the 
Cockcroft-Gault equation (CG), four- and six-variable Mod-
ification of Diet in Renal Disease equation (MDRD4 and 
MDRD6), and the more recently described Chronic Kidney 
Disease Epidemiology Collaboration equation (CKD-EPI) 
(6-8). Recently, the CKD-EPI equation was shown to out-
perform the MDRD4 equation in chronic heart failure (CHF) 
patients in terms of accuracy and precision (9) and for mor-
tality prediction (10,11).
Accuracy of equations based on serum creatinine concen-
tration is affected by different demographic variables. Se-
rum creatinine concentration depends on renal function 
but is also associated with muscle mass, ie, body compo-
sition (12). Generally, inclusion of lean body mass into the 
calculation improved the glomerular filtration rate (GFR) 
estimation (13). However, some studies suggest that this 
is restricted to overweight patients (14). These studies 
were performed in patients with chronic kidney disease or 
healthy individuals, and there is a lack of information on 
CHF patients.
A significant proportion of CHF patients with systolic dys-
function develop a rapid decline in renal function, regard-
less of their baseline renal function. Among all patients 
with heart failure, the prevalence of some degree of chron-
ic kidney disease is between 25% and 63% (15,16). In this 
population, the rate of decline is a strong predictor of in-
creased mortality (1). Previous studies that investigated the 
performance of different equations over time were mostly 
performed in patients with kidney disease and no similar 
study was conducted in patients with CHF (17,18).
We aimed to compare the performance of iohexol plasma 
clearance and creatinine-based glomerular filtration esti-
mating equations (CG, MDRD, CKD-EPI) in 6-month renal 
function estimation in CHF patients. We also investigated 
the association of estimates with body composition eval-
uated using bioimpedance analysis (BIA) and dual-en-
ergy x-ray absorptiometry (DEXA).
MATerIALS AnD MeTHoDS
Participants and study design
Consecutive patients with CHF diagnosed according to 
European Society of Cardiology guidelines attending our 
outpatient clinic were screened for inclusion between No-
vember 2011 and February 2013. We excluded patients 
who had estimated glomerular filtration rate (eGFR) with 
MDRD4 < 30 mL/ (min ×1.73 m2) at baseline visit to main-
tain iohexol sampling interval of 4 hours (5,19). Measure-
ments and patient evaluation were performed at baseline 
and at least 6 months thereafter (follow-up). All patients 
had to be without acute deterioration of heart failure (re-
quiring hospitalization or change in therapy) for at least 
four weeks before both visits. Patients attended the clin-
ic in the morning, after overnight fasting, and before tak-
ing their prescribed drug therapy. Blood biomarkers, io-
hexol clearance, and body composition were determined 
at both visits. The protocol was approved by the Repub-
lic of Slovenia National Medical Ethics Committee and the 
trial was registered at ClinicalTrials.gov (NCT01829880). Pa-
tients received verbal and written information about the 
study and provided written informed consent before any 
study-related procedure.
Determination of measured glomerular filtration rate 
(mGFr)
Iohexol solution (5 mL of Omnipaque 300 ®, GE Health-
care, Cork, Ireland) was administered by intravenous in-
jection. Blood samples were drawn into lithium heparin-
ized tubes before administration of iohexol 3 hours and 
4 hours post administration. Blood was centrifuged im-
mediately (15 min, 5°C, 3500 g) and plasma was stored at 
-80°C for further analyses. The samples were analyzed on 
a continuous basis (to avoid any storage driven analyti-
cal mistakes) throughout the study. Plasma concentration 
of iohexol was measured as described later in the text. 
Clearance of iohexol was calculated based on a one-com-
partment model utilizing measured 3-hour and 4-hour io-
hexol concentrations and applying Bröchner-Mortensen 
correction (4,20).
Blood biomarkers
Blood biomarkers (serum creatinine, urea, albumin, N-
terminal pro B-type natriuretic peptide, electrolytes, and 
complete blood count) were determined in a blood sam-
ple drawn before administration of iohexol. Serum creati-
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nine concentration was measured by the kinetic Jaffe re-
action, rate-blanked and compensated on a Cobas 6000 
analyzer (Roche Diagnostics, Basel, Switzerland). The meth-
od is standardized to Isotope Dilution Mass Spectrometry 
method.
Determination of estimated glomerular filtration rate 
(eGFr)
eGFR was calculated on the basis of serum creatinine con-
centration and other variables using the following five 
equations: CG, CG adjusted for lean body mass (GCLBM), 
MDRD4, MDRD6, and CKD-EPI equation (6-8). Creatinine 
clearance (ClCr) using CGLBM was calculated as shown in 
Equation 1. Lean body mass (LBM), used for calculation, 
was measured with DEXA or (in patients where DEXA was 
not performed) with BIA.
                  Equation 1.
SCr is serum creatinine concentration (in μmol/L). eGFR was 
calculated in mL/ (min ×1.73 m2) for all five equations. To 
transform the units of CG and CGLBM equations from mL/
min to mL/(min ×1.73 m2), body surface area was calcu-
lated using the DuBois equation (21).
Body composition measurement
At both visits, body composition was determined by BIA 
and DEXA. BIA was performed in fasting patients after 10 
minutes of supine rest with Bodystat 1500 analyzer (Bodys-
tat Ltd, Isle of Man, UK). Fat mass (in kg and %), lean mass 
(in kg and %), dry lean mass (in kg and %), and water con-
tent (in liters and %) was recorded. Four patients with pace-
makers did not undergo this test.
Full body scan DEXA was performed with Hologic Explorer, 
QDR Series (Hologic Inc., Waltham, MA, USA) to assess fat 
mass (in kg and %), lean mass (in kg and %), and bone min-
eral content (in kg). The sum of lean mass in both arms and 
legs was calculated to obtain appendicular skeletal mus-
cle mass, and skeletal muscle index was calculated with 
Equation 2 (22). Fat-free mass was calculated as the sum of 
lean mass and bone mineral content measured by DEXA, 
and fat-free mass index was calculated using Equation 3. A 
DEXA scan was not recorded in one patient at baseline and 
in three patients at follow-up due to lack of availability of 
the device at the time of the visit.
                                                        Equation 2
Where SMI is skeletal muscle index and ASM is appendicu-
lar skeletal muscle mass.
                                                   Equation 3
Where FFMI is fat-free mass index and FFM is fat-free mass.
Measurement of iohexol in plasma
Plasma concentration of iohexol was measured with an 
isocratic reversed-phase high-performance liquid chro-
matography coupled with an UV detector. The method, 
which was previously described (23), was internally op-
timized and validated before use. 200 μL of 5% perchlo-
ric acid was added to 100 μL of plasma and mixed with a 
vortex mixer for 3 min. The samples were put in an ultra-
sonic bath for 5 min, followed by centrifugation (10 min, 
10 000 g, 4°C). 70 μL of 2.5% ammonia solution was added 
to 100 μL of the supernatant and mixed with a vortex mix-
er for 30 s. The obtained solution was analyzed by high-
performance liquid chromatography system. The chro-
matographic separation was achieved on a Synergi Hydro 
250 × 4.60 mm column with 4 µm particles, guarded by 
a C18 guard column (Phenomenex, Torrance, CA, USA) at 
40°C. The mobile phase consisted of a mixture of 50 mM 
phosphate buffer (pH 3): acetonitrile (94:6%v/v) and the 
flow rate was 1.0 mL/min. The UV-detection was carried 
out at 254 nm.
Statistical analysis
Data are presented with a mean value ± standard devia-
tion or median and range. Two tailed P values lower than 
0.05 were considered statistically significant. Kolmogorov-
Smirnov test showed a normal distribution of all values 
included in linear regression and/or paired sample t tests 
(P > 0.05). All calculations were performed with SPSS for 
Windows 19.0 (IBM Corp, Armonk, NY, USA).
Linear regression was used to determine the extent of lin-
ear dependence between numerical patients’ characteris-
tics and mGFR and changes in mGFR (Pearson correlation). 
Paired sample t test was used to compare mGFR and pa-
tients’ parameters at both visits, and an independent sam-
ple t test was used to compare the influence of different 
categorical variables on mGFR. In cases of linear regression 
with multiple comparisons employed on the same data 
set, Bonferroni correction was used. The paired sample t 
test with multiple comparisons was done in SPSS and P 
values were adjusted for Bonferroni correction.
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Absolute differences between eGFR and mGFR were calcu-
lated with Equation 4 and PE with Equation 5.
 Equation 4
                                       Equation 5
Where eGFR is estimated glomerular filtration rate, mGFR 
is measured glomerular filtration rate, and PE is percent-
age error.
Mean PE, absolute difference in mL/(min ×1.73 m2), per-
centage of estimated GFR within 30% of measured GFR 
(P30), and correlation coefficients were calculated for all 
equations at both visits. Bland-Altman plots were drawn 
for all equations at baseline. Linear regression was used to 
evaluate PE of equations with both mGFR and parameters 
of body composition at baseline. Additionally, multiple lin-
ear regression was performed to assess whether equations 
with included percentage lean body mass (measured with 
DEXA at baseline visit) better predicted mGFR (α = 0.001, 
“enter” method). Percentage lean body mass was chosen 
to be included into the model on the basis of results of 
Pearson correlation between various body composition 
parameters and mGFR.
FIGure 1. Flowchart.
TABLe 1. Baseline patients’ characteristics (n = 43)*
Characteristic
Sex (% male)   58
NYHA class I/II/III, N (%)    2 (5)/35 (81) /6 (14)
Mean (standard deviation)
Age (years)   73 (9)
Weight (kg)   81 (18)
BMI   29.5 (6.0)
BSA (m2)    1.9 (0.2)
Mean SBP (mmHg)  131 (18)
Mean DBP(mmHg)   71 (11)
Mean heart rate (min-1)   72 (16)
LVEF (%)   47.8 (13.3)
Hematocrit (%)   40.0 (4.0)
Serum NT-proBNP (ng/L) 2 329 (2,161)
Serum urea (mmol/L)    9.6 (3.6)
Serum albumin (g/L)   44.9 (2.9)
Serum creatinine (μmol/L)  105 (28)




Atrial fibrillation  58
Coronary artery disease  21
Diabetes mellitus  16
Chronic obstructive pulmonary disease   5
Hypercholesterolemia  54
Medication
ACEi or ARB  98
Beta blockers 100
MRA  58
Loop diuretics  63
Thiazide or thiazide-like diuretics  19
Warfarin  67
Antiaggregation therapy  23
Methyldigoxin  19
Calcium channel blockers  19
Statins  56
*nYHA – new York Heart Association Functional Classification; BMI 
– body mass index; BSA – body surface area; SBP – systolic blood 
pressure; DBP – diastolic blood pressure; nT-proBnP – n-terminal 
prohormone of brain natriuretic peptide; CL – clearance; ACei – 
angiotensin-converting-enzyme inhibitor; ArB – angiotensin receptor 
blocker; MrA – mineralocorticoid receptor antagonist.
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reSuLTS
49 patients were screened for inclusion. 2 patients did not 
consent to take part in the investigation, 1 patient report-
ed a history of severe allergic reactions to drugs, 1 patient 
had an eGFR below 30 mL/(min ×1.73 m2), and 2 patients 
were additionally excluded from the analysis due to inap-
propriate iohexol administration. Accordingly, 43 patients 
with CHF (58% male, mean age 73 years) were included 
into the study, and 31 patients had a follow-up iohexol as-
sessment (3 patients died, 7 declined to participate, and 
2 had inappropriate iohexol administration) (Figure 1). The 
TABLe 3. Performance of equations on baseline and follow-up*

























CL iohexol 53.1 44.4
MDRD4 57.9 11.6 4.83 0.712 88.4 56.2 33.6 11.8 0.759 51.6
MDRD6 61.2† 11.7† 7.67† 0.699 78.6 59.8‡ 41.3‡ 15.1‡ 0.740 43.3
CG 57.9 12.0 4.79 0.537 72.1 57.5 35.7 13.1 0.781 48.4
CGLBM 36.4 - 30.5 - 16.7 0.726 44.2 36.2 - 15.9 - 8.23 0.832 74.2
CKD-EPI 49.3 - 4.86 - 3.75 0.540 81.4 49.2 16.7 4.80 0.658 74.2
*GFr – glomerular filtration rate; MPe – mean percentage error; MDrD4 – four-variable Modification of Diet in renal Disease equation; MDrD6 – six-
variable Modification of Diet in renal Disease equation; CG – Cockcroft-Gault equation; CGLBM –Cockcroft-Gault equation adjusted for lean body 
mass; CKD-ePI – Chronic Kidney Disease epidemiology Collaboration equation. P30 – percentage of estimated GFr within 30% of measured GFr.
†n = 42.
‡n = 30.
§P < 0.001 for all equations
TABLe 2. Measured renal function, serum markers, and body composition parameters at baseline and follow-up (n = 31)*
Baseline mean (SD) Follow-up mean (SD) P
CL iohexol (mL/[min ×1.73 m2])  52.8 (19.1)  44.4 (20.6) 0.001
Serum creatinine (μmol/L) 106 (28) 108 (33) 0.561
Serum urea (mmol/L)   9.8 (3.9)   9.6 (3.7) 0.700
Serum albumin (g/L)†  45.1 (3.0)  43.7 (3.5) 0.014
Body weight (kg)  83.0 (18.6)  83.0 (19.7) 0.954
BMI  30.3 (5.7)  30.2 (6.2) 0.805
BSA   1.90 (0.24)   1.90 (0.25) 0.968
BIA (n = 27)
Fat (kg)  30.1 (10.3)  31.1 (11.7) 0.092
Fat (%)  36.0 (8.5)  37.0 (9.2) 0.033
Lean (kg)  53.3 (13.1)  52.4 (13.5) 0.080
Lean (%)  64.1 (8.4)  63.0 (9.2) 0.021
Dry lean (kg)  10.6 (5.1)  10.4 (5.5) 0.197
Dry lean (%)  12.2 (4.7)  11.8 (5.3) 0.106
Water (L)  42.6 (8.2)  42.0 (8.3) 0.104
Water (%)  51.8 (6.4)  51.2 (7.2) 0.275
DeXA (n = 27)
Fat (kg)  27.2 (11.0)  28.0 (10.4) 0.044
Fat (%)  32.7 (8.8)  33.4 (7.8) 0.112
Lean (kg)  51.9 (10.8)  52.0 (11.1) 0.753
Lean (%)  64.4 (8.3)  63.6 (7.4) 0.081
SMI   7.27 (1.45)   7.37 (1.41) 0.454
FFMI  19.27 (2.49)  19.31 (2.80) 0.741
*CL – clearance; BMI – body mass index; BSA – body surface area; BIA – bioimpedance analysis; DeXA – dual-energy x-ray absorptiometry; BMC – 
bone mass content; FFMI – fat-free mass index; SMI – skeletal muscle index; SD – standard deviation.
†n = 29.
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mean follow-up time was 8 months (median 7.5 months, 
range 6-17 months). Baseline patients’ characteristics and 
renal function are presented in Table 1. 16 patients (37%) 
had left ventricular ejection fraction ≤40%. Their mean 
mGFR was 53.1 mL/(min ×1.73 m2), with mGFR below 30 
mL/(min ×1.73 m2) in 2 (5%) patients, between 30 and 60 
mL/(min ×1.73 m2) in 26 (61%) patients, and over 60 mL/
(min ×1.73 m2) in 15 (35%) patients.
At baseline, mGFR was inversely correlated with age 
(r = −0.354, P = 0.002). Among concomitant diseases and 
drug therapy, only arterial hypertension was associated 
with poorer renal function (52.9 vs 69.4 mL/min, P = 0.014). 
Different parameters of body composition were correlated 
with baseline mGFR: fat mass in kg (r = -0.331, P = 0.032), 
percentage fat mass (r = -0.383, P = 0.012), and percentage 
lean mass (r = 0.388, P = 0.011).
Serum biomarkers did not significantly change between 
the two visits, except for serum albumin (Table 2). Body 
weight and most parameters of body composition (ex-
cept body fat and lean mass) also remained stable (Ta-
ble 2). mGFR significantly declined during the follow-up 
(from 52.8 to 44.4 mL/[min ×1.73 m2], P = 0.001, Figure 2 
and Supplementary Figure 1). Serum creatinine concen-
tration remained unchanged, leaving the decline in mGFR 
undetected by equations (Table 3). In 6 patients, mGFR 
decreased from >60 mL/(min ×1.73 m2) to 30-60 mL/(min 
×1.73 m2) and in additional 6 patients from 30-60 mL/(min 
×1.73 m2) to <30 mL/(min ×1.73 m2).
The mean PE and absolute differences between eGFR and 
mGFR tended to increase toward positive values from base-
line to follow-up visit (Table 3). CKD-EPI had the lowest 
mean absolute difference between eGFR and mGFR as well 
as the mean PE. Also CG, MDRD4, and MDRD6 estimated 
renal function at baseline considerably well, but at follow-
up they overestimated renal function by more than 30%. 
CGLBM was the only equation that underestimated GFR at 
both visits. Bland-Altman plots for all equations at baseline 
are presented in Figure 3. PE of all equations was inversely 
correlated with mGFR, which suggests that they overesti-
mate renal function when mGFR levels are low and under-
estimate it when mGFR levels are high (data not shown).
The accuracy of CG, CGLBM, and CKD-EPI equations was 
associated with body composition parameters, while the 
accuracy of MDRD4 and MDRD6 was not (Supplementa-
ry Table 1 and Supplementary Table 2). Linear regression 
showed that mass was positively associated, while lean 
body mass and water were negatively associated with PE. 
Multiple linear regression revealed that additional 23% of 
the variance in mGFR can be explained by adding per-
centage of lean body mass (measured with DEXA) to CG 
equation. This percentage was 15.3% for CKD-EPI and 4.0% 
for the CGLBM equation, while the improvement did not 
reach statistical significance for MDRD4 and MDRD6 equa-
tions (Supplementary Table 2).
Between the two visits, mGFR declined for more than 15 
mL/(min ×1.73 m2) in 26% of patients and did not decline 
in 26% of patients (Figure 4). eGFR declined for more than 
15 mL/(min ×1.73 m2) in only 3%-6% of patients and did 
not decline in 45%-52% of patients.
The decline in mGFR was not related to any baseline char-
acteristic with the exception of mineralocorticoid receptor 
antagonists (spironolactone or eplerenone) prescription 
at baseline (Figure 5). Patients receiving mineralocorticoid 
receptor antagonists at baseline had a mean decline in 
mGFR of 22% of baseline value and patients not receiving 
this therapy had a mean decline of 3%. The difference in 
renal function decline was also detected with equations, 
although only CGLBM equation detected the difference 
with statistical significance (P < 0.050).
The percentage change in mGFR was correlated with 
changes in demographic parameters and parameters of 
body composition between both visits. A significant cor-
relation was observed between change in body weight 
(r = 0.386, P = 0.032), body surface area (r = 0.358, P = 0.048), 
FIGure 2. Decline in measured glomerular filtration rate dur-
ing follow up (n = 31).
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systolic blood pressure (r = 0.405, P = 0.024), serum urea 
concentration (r = −0.507, P = 0.004), and serum creatinine 
concentration (r = −0.427, P = 0.016).
DISCuSSIon
This is the first prospective longitudinal study that assessed 
both measured and estimated renal function in patients 
with CHF treated according to guidelines. Measurement 
with iohexol demonstrated a significant decline of renal 
function, most prominent in patients treated with miner-
alocorticoid receptor antagonists, those who experienced 
weight loss, or those with increased serum urea concen-
tration. No equation for estimation of renal function per-
formed similarly to mGFR and thus was unable to detect 
the significant decline of renal function. In clinical practice, 
this can cause inappropriate risk stratification or therapeu-
tic decisions with potential harm to the patient.
FIGure 3. Bland-Altman plots for creatinine-based renal function estimating equations at baseline visit. CL – clearance, CG – Cock-
croft-Gault equation, CGLBM –Cockcroft-Gault equation adjusted for lean body mass, CKD-ePI – Chronic Kidney Disease epidemiol-
ogy Collaboration equation, MDrD4 – four-variable Modification of Diet in renal Disease equation, MDrD6 – six-variable Modifica-
tion of Diet in renal Disease equation.
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The decline of renal function in patients with heart failure 
was previously evaluated by Khan et al (1) using equations 
for estimation of renal function. In this study, 6640 patients 
were followed for a mean of 34 months and MDRD4 de-
tected a rapid decline of renal function, with one-third of 
patients experiencing a decline greater than 5 mL/min per 
year and an additional third experiencing a decline of up to 
5 mL/min per year. However, this was a retrospective analy-
sis, with a potential bias of patients being in a non-stable 
condition and without validation with an external marker 
of renal function. In our study, patients were treated ac-
cording to guidelines and were in a stable condition, the 
equations detected no decline of renal function in 50% 
of our patients, while only 25% had stable renal function 
measured with iohexol. Our results are consistent with oth-
er findings regarding the decline in eGFR, but cannot be 
compared in terms of mGFR since previous studies did not 
prospectively evaluate mGFR in patients with CHF (1,24).
Mineralocorticoid receptor antagonist usage was the only 
baseline characteristic that predicted mGFR decline. It is 
not clear whether this is a consequence of drug therapy 
alone or of more progressive disease in patients who take 
mineralocorticoid receptor antagonists. While mineralo-
FIGure 4. Decline of renal function during follow-up (n = 31). CG – Cockcroft-Gault equation, CGLBM – Cockcroft-Gault equation 
adjusted for lean body mass, CKD-ePI – Chronic Kidney Disease epidemiology Collaboration equation, CL – clearance, MDrD4 – four-
variable Modification of Diet in renal Disease equation, MDrD69 – six-variable Modification of Diet in renal Disease equation.
FIGure 5. Change in renal function during follow-up according to prescription of min-
eralocorticoid receptor antagonists at baseline. CG – Cockcroft-Gault equation, CGLBM 
–Cockcroft-Gault equation adjusted for lean body mass, CKD-ePI – Chronic Kidney 
Disease epidemiology Collaboration equation, CL – clearance, MDrD4 – four-variable 
Modification of Diet in renal Disease equation, MDrD6 – six-variable Modification 
of Diet in renal Disease equation, MrA – mineralocorticoid receptor antagonist 
(spironolactone or eplerenone).
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corticoid receptor antagonist treatment is beneficial for 
patients with CHF, it may carry a risk of renal function wors-
ening with increased mortality (25-27).
Renal function was overestimated by both MDRD equa-
tions, CG equation at baseline, and CKD-EPI equation at 
follow-up. As mGFR declined from baseline to follow-up, 
mean PE and absolute differences tended to increase to-
ward positive values for all equations. Both MDRD equa-
tions and CG equation overestimated mGFR by 12 to 15 
mL/(min ×1.73 m2) at follow-up. Similar absolute overesti-
mation (10 to 15 mL/[min ×1.73 m2]) was observed in the 
study by O’Meara et al (28), where mean mGFR of heart fail-
ure patients (46.9 mL/[min ×1.73 m2]) was comparable to 
the mean mGFR in our patients at follow-up (44.6 mL/[min 
×1.73 m2]). Two other studies in heart failure patients found 
that equations underestimated mGFR, but these were per-
formed in populations with mean GFR higher than 70 mL/
(min ×1.73 m2) (9,29). CGLBM equation was the only equa-
tion that underestimated mGFR at both visits.
The accuracy of CG, CGLBM, and CKD-EPI equation was re-
lated to body composition parameters and could be partly 
improved by inclusion of lean mass into the calculation. In 
patients with a lower percentage of lean mass there was a 
greater risk of renal function overestimation, while in pa-
tients with a higher percentage of lean mass there was a 
greater risk of its underestimation. This could be due to the 
relationship among lean mass, muscle mass, and serum 
creatinine concentration. In extremely underweight or 
obese patients, estimation of renal function with CG and 
CKD-EPI equations could lead to greater prediction errors, 
which can be partly improved by body composition mea-
surement.
We were not able to explain equations’ failure to detect re-
nal function decline with changes in body composition. 
Moreover, MDRD equations, which do not include body 
composition parameters, also followed the same trend. 
The reasons for failure are likely to be complex and mul-
tifactorial. Previous studies have already shown that equa-
tions perform poorly for longitudinal monitoring of renal 
function because of increased fraction of creatinine tubu-
lar secretion in the failing kidney (30,31). Furthermore, the 
blockade of renin-angiotensin system was shown to fur-
ther increase tubular secretion of creatinine, leaving serum 
creatinine concentration unchanged regardless of GFR de-
cline (32). In our study, all patients were treated with an-
giotensin-converting-enzyme inhibitors or angiotensin 
receptor blockers. Since this is a fundamental therapy in 
heart failure, renal function monitoring with equations in 
this population could be inaccurate.
This study has several limitations. With a study sample of 
31 patients who took part in the follow-up, generalizibility 
of results is limited and confirmatory studies are needed. 
However, the observed renal function decline was consis-
tent over the entire patient group and was clinically sig-
nificant. The GFR was estimated at a single point in time 
at baseline and follow-up and may thus not completely 
reflect dynamic longitudinal changes of kidney function. 
Additionally, the MDRD equations were also applied in pa-
tients with GFR over 60 mL/(min ×1.73m2), although this is 
not a recommended approach. However, we aimed to use 
the same approach for all equations in order to estimate 
which equation is best for CHF patients regardless of their 
kidney function. The influence of body composition on the 
accuracy of GFR estimation was studied in both sexes, not 
taking into consideration the body composition differenc-
es between the sexes. Renal function declined during fol-
low-up, but the same protocol for renal function measure-
ment with iohexol was applied at both visits. For patients 
with GFR<30 mL/(min ×1.73 m2), this could be relevant as 
iohexol clearance is expected to overestimate renal func-
tion with sampling times shorter than 4 hours. However, 
this was clearly demonstrated only for one-sample pro-
tocol (33), while we determined iohexol clearance at two 
time points. The patients in whom mGFR increased during 
follow up were found in all ranges of mGFR, so the increase 
in mGFR is not likely to be due to inadequate sampling 
time. Moreover, if the overestimation was indeed pres-
ent, our results would be even more alarming as true renal 
function would be even lower than actually measured.
In conclusion, mGFR outperformed the equations in CHF 
patients, and did so across all stages of chronic kidney dis-
ease. Patients receiving mineralocorticoid receptor antag-
onists were more prone to develop a rapid decline in renal 
function. All tested equations correlated well with mGFR, 
but their overestimation increased as mGFR decreased. Due 
to their dependence on body composition parameters, CG 
and CKD-EPI equations should be used with caution in ex-
tremely underweight or obese patients. In clinical practice, 
eGFR appears to be insufficient to detect clinically relevant 
changes in renal function, which is why pharmacological 
therapy may be delayed or not modified, exposing some 
of the patients to increased risk of complications. Howev-
er, eGFR cannot be replaced by an exogenous marker of 
renal function, but rather with a different endogenous 
marker. Our results also imply that eGFR may not be 
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an ideal primary end-point in patients with CHF. Further 
studies with larger sample size and longer follow-up are 
needed to clarify this issue.
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